CN114249816B - 一种重组蛋白质药物的分子设计 - Google Patents

一种重组蛋白质药物的分子设计 Download PDF

Info

Publication number
CN114249816B
CN114249816B CN202111201002.3A CN202111201002A CN114249816B CN 114249816 B CN114249816 B CN 114249816B CN 202111201002 A CN202111201002 A CN 202111201002A CN 114249816 B CN114249816 B CN 114249816B
Authority
CN
China
Prior art keywords
ser
leu
ala
gly
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202111201002.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN114249816A (zh
Inventor
罗永章
刘鹏
鲁薪安
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsinghua University
Protgen Ltd
Original Assignee
Tsinghua University
Protgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsinghua University, Protgen Ltd filed Critical Tsinghua University
Priority to CN202111201002.3A priority Critical patent/CN114249816B/zh
Publication of CN114249816A publication Critical patent/CN114249816A/zh
Application granted granted Critical
Publication of CN114249816B publication Critical patent/CN114249816B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CN202111201002.3A 2015-02-13 2016-02-14 一种重组蛋白质药物的分子设计 Active CN114249816B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111201002.3A CN114249816B (zh) 2015-02-13 2016-02-14 一种重组蛋白质药物的分子设计

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2015100794867 2015-02-13
CN201510079486 2015-02-13
CN201510736184 2015-11-02
CN2015107361842 2015-11-02
CN202111201002.3A CN114249816B (zh) 2015-02-13 2016-02-14 一种重组蛋白质药物的分子设计
PCT/CN2016/073773 WO2016127948A1 (zh) 2015-02-13 2016-02-14 一种重组蛋白质药物的分子设计
CN201680010044.XA CN107428809B (zh) 2015-02-13 2016-02-14 一种重组蛋白质药物的分子设计

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680010044.XA Division CN107428809B (zh) 2015-02-13 2016-02-14 一种重组蛋白质药物的分子设计

Publications (2)

Publication Number Publication Date
CN114249816A CN114249816A (zh) 2022-03-29
CN114249816B true CN114249816B (zh) 2024-09-06

Family

ID=56614147

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680010044.XA Active CN107428809B (zh) 2015-02-13 2016-02-14 一种重组蛋白质药物的分子设计
CN202111201002.3A Active CN114249816B (zh) 2015-02-13 2016-02-14 一种重组蛋白质药物的分子设计

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201680010044.XA Active CN107428809B (zh) 2015-02-13 2016-02-14 一种重组蛋白质药物的分子设计

Country Status (8)

Country Link
US (2) US10869910B2 (enExample)
EP (1) EP3269731B1 (enExample)
JP (1) JP6896636B2 (enExample)
CN (2) CN107428809B (enExample)
AU (2) AU2016218635B2 (enExample)
CA (1) CA3014538A1 (enExample)
DK (1) DK3269731T5 (enExample)
WO (1) WO2016127948A1 (enExample)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101890155A (zh) * 2010-05-25 2010-11-24 江苏先声药物研究有限公司 一种药物组合物及其应用
WO2013034116A1 (zh) * 2011-09-09 2013-03-14 清华大学 对atp结合位点进行突变的血管内皮抑制素突变体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114558111A (zh) * 2014-11-03 2022-05-31 清华大学 一种抑制脂肪细胞分化和胰岛素耐受的药物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101890155A (zh) * 2010-05-25 2010-11-24 江苏先声药物研究有限公司 一种药物组合物及其应用
WO2013034116A1 (zh) * 2011-09-09 2013-03-14 清华大学 对atp结合位点进行突变的血管内皮抑制素突变体

Also Published As

Publication number Publication date
DK3269731T5 (da) 2024-10-14
DK3269731T3 (da) 2023-10-30
EP3269731A4 (en) 2018-08-15
CA3014538A1 (en) 2016-08-18
US20210085754A1 (en) 2021-03-25
CN114249816A (zh) 2022-03-29
EP3269731B1 (en) 2023-10-04
CN107428809B (zh) 2021-10-01
AU2020256316A1 (en) 2020-11-12
CN107428809A (zh) 2017-12-01
JP2018507854A (ja) 2018-03-22
AU2020256316B2 (en) 2021-10-07
AU2016218635A1 (en) 2017-10-05
US10869910B2 (en) 2020-12-22
WO2016127948A1 (zh) 2016-08-18
US20180200337A1 (en) 2018-07-19
JP6896636B2 (ja) 2021-06-30
AU2016218635B2 (en) 2020-07-23
EP3269731A1 (en) 2018-01-17

Similar Documents

Publication Publication Date Title
CN101010338B (zh) 成纤维细胞生长因子21的突变蛋白
JP2023040155A (ja) 組換え神経成長因子のための組成物及び方法
CN110546161A (zh) 对胰岛素受体具有降低的结合力的胰岛素类似物及其用途
US11041157B2 (en) Slit2D2-HSA fusion protein and use thereof against tumours
CN1367791A (zh) 一种新的血管发生抑制剂
WO2010120931A2 (en) E2f as a target for treatment of hormone refractory prostate cancer
CN114796525B (zh) 细胞周期调控蛋白抑制剂在肿瘤治疗中的应用
JP7531931B2 (ja) Ｖｇｌｌ１ペプチドを含む癌治療用組成物
CN112851791B (zh) 一种新型抗代谢紊乱的fgf类似物及其应用
CN117157308A (zh) 细胞穿膜肽变体及其用途
CN106432483B (zh) 沼水蛙皮肤丝氨酸蛋白酶抑制肽及其基因和制药应用
CN114249816B (zh) 一种重组蛋白质药物的分子设计
WO2015055148A1 (zh) Yap蛋白抑制多肽及其应用
HK1240943B (zh) 一种重组蛋白质药物的分子设计
US6893844B1 (en) DNA encoding a new human hepatoma derived growth factor and producing method thereof
CN110520144B (zh) 肽激酶抑制剂及其使用方法
WO2004091650A1 (fr) Utilisation de la troponine i cardiaque pour preparer des medicaments antitumoraux
CN116789750B (zh) 预防和/或治疗宫颈癌的多肽及其应用
HK1240943A1 (en) Molecular design of recombinant protein drug
CN109776685A (zh) 融合蛋白hBD2-haFGF1及其制备方法和应用
US7361486B2 (en) Polynucleotide, vector, host cell and method for producing human hepatoma-derived growth factor 5 polypeptide
CN117384269A (zh) 短肽mfrlp及其在制备动脉重塑相关疾病药物中的应用
CN102212126B (zh) 具有抑制内皮细胞生长活性的重组EDI-8t蛋白
CN119591675A (zh) 多肽、核酸、表达载体、药物组合物及其用途
JPWO2006057389A1 (ja) Ａｍｐプロテインキナーゼによってリン酸化される新規転写因子とその遺伝子

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant